PRKDC and neoplasm: Another study identified that the AKT inhibitor MK2206, the DNA-PK inhibitor NU7441, and the MEK inhibitor trametinib increase the ability of a DCV to activate and expand tumor-reactive T cells and augment antitumor activity in glioblastoma mice 121.